Results 261 to 270 of about 2,034,935 (392)

Molecular detection of pathogens in an equine fever diagnostic panel: 2019–2023

Equine Veterinary Journal, EarlyView.
Abstract Background A common diagnostic approach for febrile horses is to test for a panel of potential pathogens. Panels are curated by expert opinion and vary between diagnostic laboratories. Objectives To report the results of a newly developed equine fever diagnostic panel (EFDP) between 2019 and 2023 and evaluate the frequency of positive results.
Toby L. Pinn‐Woodcock, Melissa S. Aprea, Manigandan Lejeune, Joy E. Tomlinson   +3 more
wiley   +1 more source

A Case of Drug-Induced Immune Thrombocytopenia Caused by Haloperidol. [PDF]

Cureus
Kanno Y, Ono Y, Takita K.
europepmc   +1 more source

Clinical signs, clinical pathology and outcomes in horses infected naturally with equine encephalosis virus

Equine Veterinary Journal, EarlyView.
Abstract Background Equine encephalosis (EE) is caused by an Orbivirus from the family Sedoreoviridae and is thus similar to African horse sickness (AHS) and Bluetongue viruses (BTV). These viruses are transmitted by Culicoides midges. Equine encephalosis can infect horses, donkeys and zebras sub‐clinically while only horses develop clinical disease ...
Graeme Piketh, Adrienne Viljoen, Christina Eberhardt   +2 more
wiley   +1 more source

Limitations of rituximab in treating primary immune thrombocytopenia and the therapeutic potentials of alternatives. [PDF]

Curr Opin Hematol
Pan L, Zhu J.
europepmc   +1 more source

The role of Janus kinase signaling in graft-versus-host disease and graft versus leukemia [PDF]

, 2018
Choi, Jaebok, DiPersio, John F, Schroeder, Mark A, Staser, Karl   +3 more
core   +2 more sources

Long‐term safety and efficacy of rituximab in 248 adults with immune thrombocytopenia: Results at 5 years from the French prospective registry ITP‐ritux

, 2019
Samuel Deshayes, Mehdi Khellaf, Anissa Zarour, Richard Layese, O. Fain, Louis Terriou, Jean‐François Viallard, Stéphane Chèze, J. Graveleau, Borhane Slama, Sylvain Audia, Manuel Cliquennois, Mikaël Ebbo, G. Le Guenno, Gilles Salles, Caroline Bonmati, F Teillet, Lionel Galicier, Olivier Lambotte, A. Hot, François Lefrère, Matthieu Mahévas, Florence Canouï‐Poitrine, Marc Michel, Bertrand Godeau   +24 more
openalex   +2 more sources

Additional efficacy analysis of avatrombopag phase III data for the treatment of adults with immune thrombocytopenia

, 2023
Shivi Jain, Terry Gernsheimer, Scott Kolodny, Chelsea Bernheisel, Michael Vredenburg, Sandhya R. Panch   +5 more
openalex   +1 more source

Incidence of systemic lupus erythematosus in patients with immune thrombocytopenia: A nationwide study

British Journal of Haematology, EarlyView.
Malin Rasmussen, Nikolaj Mannering, Henrik Frederiksen   +2 more
wiley   +1 more source

Classification of Platelet‐Activating Anti‐Platelet Factor 4 Disorders

International Journal of Laboratory Hematology, EarlyView.
ABSTRACT Introduction The prototypic anti‐platelet factor 4 (PF4) disorder—heparin‐induced thrombocytopenia and thrombosis (HITT)—features immunoglobulin G (IgG) class antibodies that activate platelets, monocytes, and neutrophils in a mainly heparin‐dependent fashion via Fcγ receptor‐dependent cellular activation.
Theodore E. Warkentin
wiley   +1 more source

Fostamatinib and the risk of acute aortic dissection in immune thrombocytopenia. [PDF]

Br J Clin Pharmacol
Dalmas P, Theron A, Badaoui R, Zaffran S, Mchinda R, Micallef J, Schleinitz N, Ebbo M.   +7 more
europepmc   +1 more source